Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Current Liabilities (2021 - 2025)

Aligos Therapeutics' Total Current Liabilities history spans 5 years, with the latest figure at $21.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 2.32% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $21.2 million, down 2.32%, while the annual FY2025 figure was $21.2 million, 2.32% down from the prior year.
  • Total Current Liabilities reached $21.2 million in Q4 2025 per ALGS's latest filing, down from $22.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $41.4 million in Q1 2022 to a low of $18.9 million in Q1 2024.
  • Average Total Current Liabilities over 5 years is $26.7 million, with a median of $24.6 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 63.91% in 2022, then tumbled 32.76% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $39.0 million in 2021, then decreased by 14.96% to $33.1 million in 2022, then decreased by 27.84% to $23.9 million in 2023, then fell by 9.07% to $21.7 million in 2024, then dropped by 2.32% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Total Current Liabilities are $21.2 million (Q4 2025), $22.0 million (Q3 2025), and $20.3 million (Q2 2025).